for in execution the call. all for the XXXX, you the successful us I'll key of of Jackie, veverimer. launch the on into and and the today you, thank Thank planning move right Tricida goal joining
quarter in Our activities fourth ensure PDUFA beyond. veverimer sales XXXX to successful multiple engaged and six are in date launch the this growth away in of year and of goal the months we and just is
evidence, to continue of patients comprehensive metabolic can months, awareness potentially bicarbonate and and we our feel campaign acidosis next disease education the support increasing progression will and acidosis slows metabolic existing our in and In function. patient's the CKD six that the serum expand CKD, communicate and improve with to
broad urgency understanding and treat a help serious patients We will to believe establish this increase of evidence to the condition. the with
the plans actions Our hires made include positions. key XXXX, and well XX significant management and both commercial extensive adding In the education payer as with engagement. as nephrologists, sales in functions, executive medical we
our people veverimer. expand exchange, branded two ensure access, XXXX, and have teams, those In setting roles the for months veverimer to additional commercialization the of of key our we to for campaign, prepare XX built first added logistics scientific marketing our already an smooth market enabled
me now highlight initiatives in Let the months. three coming major
disease our team; medical by market peer-to-peer second, by with affairs marketing First, managers; approved. nephrologists access our and and ensure engagement to by field-based coverage if team of payer strategic our appropriate team veverimer interactions account education awareness third,
National medical science Our leads a medical affairs, be March. deployed and successful and just meeting Kite and the She will made at with where has at team team the and Kidney Pharmacyclics this MSL end includes year medical medical significant professionals Amgen. in engage now led us Spring place late and liaison in affairs has roles The has at impact. last Foundation of is already joined a and to team medical Faust career at Celgene upcoming or nephrologists. affairs teams long key the she XX and Elizabeth
of the metabolic metabolic reviewing professionals, peer-reviewed acidosis the acidosis body serious we evidence complications on dozen April, nearly publications community to pathophysiology answering about the and expect with nephrologists of the leaders, link of hundreds CKD engaging of have By and key of MSLs care to a opinion health and progression. questions the growing
But Our from impediment acidosis than probably FDA-approved despite the to metabolic believe, to is with why metabolic their treatment acidosis. patients. therapy and that the clinical limitations We, an treatment multiple will of they of patients an to used guidelines, currently the of with disease practice play say in MSLs in XX% that to bicarbonate indicating manage of talked sodium nephrologists role bicarbonate are necessary, metabolic of metabolic the the would evidence suggests we of understanding manage acidosis independent sodium important our course sources CKD bicarbonate. treated non-sodium-sensitive actually lack is that less and so acidosis sodium furthering also primary CKD undertreated. Most
that Two X.X times little grams, to typically placebo placebo-controlled to doses very of no used studies, manage in were sodium practice, of bicarbonate today ineffective. difference metabolic active bicarbonate clinical acidosis the three common the sodium these doses most bicarbonate in clinical sodium mean between showed is daily that studies recent levels multicenter bicarbonate groups showed used benefits In treatment. one achieved and and the sodium
RENAAL patients angiotensin of with that, proven been bicarbonate recommending one the in impact their receptor creatinine blockers have higher classes patients are and or nephrologists slow medium the II rennin XX-hour low, reductions or angiotensin ARBs concern sodium with progression. is non-RAAS inhibitor system effectiveness of the analysis administered levels only inhibitors. of sodium sodium RAAS associated and that ratio high inhibitors been aldosterone A combined RAAS has of intake Another IDNT in CKD to of inhibitor-treated trials, significant patients. agents have data post-hoc The versus of the to from evaluated
therapy sodium, certain annihilated. were sodium effects The and a treatment the intake the compared of quote heart, cardiovascular larger with subjects and with consumption inhibitor-based renal that on publications, non-RAAS subjects effects the authors concluded attenuated of outcomes directly with I from in RENAAL therapy the highest cardiovascular ARB and protective completely
with cannot intake. and of hypertension, level patients an Approximately inhibitors these RAAS XX% treated with elevated manage of patients are to therefore, CKD afford their sodium
our Back to MSLs.
patients and the ULTIMA-CKD our registry acidosis Registry. CKD important publications to enabling with advance clinically effects into Another in in critical giving and by real-world the generate be This CKD. us to acidosis will MSLs Patient participate will role of of insight us metabolic of our nephologists recruiting metabolic understanding
medical communications The key generated together national, acidosis local identify to a efficacy topics to medical number bringing congresses, in leaders experts now CKD. of importantly related are of complications in effort and work affairs growing publications, participation in with that metabolic have regional in with patients leading engaging nephrology. groups through and opinion includes We nephrology we key with the
meeting we on our and we Conference to had accepted XX are publications have year. presentation in Spring double Arizona, XXXX, the Southwest way. already well for In XX abstracts Nephrology NKF we this that and so the at been aim
to over also covering education or are has medical CKD nephrologists. and three sponsored acidosis. continuing to reach medical is general metabolic committed education anticipated X,XXX programs Tricida and These independent CME courses
Now led Susannah turning by team commercial to Cantrell. our
nephrologists know awareness you has on both fronts commercial with made is progress our As peers leadership significant preparing She has the significant experience for branded disease Susannah and Gilead from and and Genentech. launch.
team, management market and product Under and we support teams infrastructure to the distribution. hired sales our entire expanded Susannah's build leadership, marketing sales access our operations and
disease website of metabolic to on nephrologists metabolic awareness messages awareness disease to expanded to familiarity in-person and Our field-based gain key us interactions also will awareness account territories. disease XX strategic most metabolic campaign drive the deployment to acidosis. the that nephrologists to significant reps the inside with with on and team targeting of acidosis digital direct stakeholders include raise XX intended in healthcare share has and deliver professionals mid-June-May for acidosis to enable be grow our the a enables been We'll support awareness our direct to recent campaign These managers. data initiating and will its other publications their complication. about This to visits key team
of approved appropriate well is initiative, Our to payers if major necessary educating tasks veverimer completing third the and underway. ensure coverage
with into Tricida's continues. early and payers has work Our this began history effort very
of from Celgene veverimer extensive engaging all payer veverimer. is Rocio aspects market Our and logistics XX the who and of consists covering in team has supply chain and to and Manghani, easier of logistics access access to team payers by managing from experience engagement Her with all Kite, Roche. distribution access professionals led to aspects
already consequences team potential metabolic million to for economic treatment real-world to insured metabolic payers FDA-approved benefits present account and and metabolic XX and acidosis of educate health first met treating a approximately as the veverimer corporate representing These lives. payers provide of us has to only potential acidosis on and Our impact acidosis. engagements enable data targeted the XXX the on
appropriate timing Payers and from shown we have market and requirements interest access which up up the support pharmacies infrastructure keen health the an coverage will the ensure specialty translate to for us early -- market These patients that hub, the have in front benefits savings. setting at for distribution retail and for the launch. access open-access to allow Also our to setting understand channel, and veverimer access veverimer to are arranging also settling up patient on to payers. broad these access enabled both significant engagements cost
in is goal access prior the PDUFA with Our XXX market date. payers meet our to to front
surveys also veverimer attitude include and with need on gauge payer the the post-meeting success message formulary. our will reaching Our right in these the confirm to payers about their
affairs focus significant these efforts, medical Beyond and to on commercial VALOR-CKD recruitment. continue we
enrolling This in post-marketing XXX VALOR-CKD sights. with large XX in made have We trial. in trial being our countries conducted patients progress outcome good approximately is
enrollment Our has subjects for the trial. been anticipate We this -- we randomizing in complete and opened target believe size year.
FDA to the committee hold continue FDA we'll or will we interactions providing routine are AdCom to review updates the complete the respect or around FDA review with other them and to submission during an our our to with work finally, not way The matters application. process planning the with say And timely accept than to on is to discussions advisory NDA, the be that in the a to the meeting manner. enable our on
occur We're of anticipating quarter and closer know XXXX that topic the discussion would meeting the date. outcome the of the likely we'll second to in
prepared evidence body of we are disease-modifying previously, rationale of potential accelerated disease. a that we and in to welcome opportunity supporting pursuing treatment progression As we this the we the be acidosis considerable metabolic approval the underlying said utilizing given and will program of closes kidney CKD, the present indication the
all ready through and clinical endpoint results on walk the the our how improvements and of surrogate and functions impact including CKD. of Furthermore, in mortality veverimer progression as to patients beyond we'll the such data be feel
that and that metabolic with provided target focused we understanding of serious increase to of FDA-approved acidosis with are veverimer to and launch is the CKD there simply to we no coverage. you a treatments understand hope payer favorable and adoption this reaching will clear believe on safe early linked condition. lead our this I for progression, audience how efficacious successful are We a
results. I'll to a financial over now turn review Geoff for of call the our
